Journal Article

DKFZ-2020-00479

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.

Hong, D. S. ; DuBois, S. G. ; Kummar, S. ; Farago, A. F. ; Albert, C. M. ; Rohrberg, K. S. ; van Tilburg, C. M.DKFZ* ; Nagasubramanian, R. ; Berlin, J. D. ; Federman, N. ; Mascarenhas, L. ; Geoerger, B. ; Dowlati, A. ; Pappo, A. S. ; Bielack, S. ; Doz, F. ; McDermott, R. ; Patel, J. D. ; Schilder, R. J. ; Tahara, M. ; Pfister, S. M.DKFZ* ; Witt, O.DKFZ* ; Ladanyi, M. ; Rudzinski, E. R. ; Nanda, S. ; Childs, B. H. ; Laetsch, T. W. ; Hyman, D. M. ; Drilon, A.

2020
The Lancet Publ. Group London

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/S1470-2045(19)30856-3

Abstract: Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.

Note: 2020 Apr;21(4):531-540

---

Contributing Institute(s):

1. KKE Pädiatrische Onkologie (B310)
2. B062 Pädiatrische Neuroonkologie (B062)

Research Program(s):

1. 312 - Functional and structural genomics (POF3-312) (POF3-312)

Appears in the scientific report 2020

---

Database coverage:
; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Ebsco Academic Search ; IF >= 30 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---